Identification of highly conserved and broadly cross-reactive HIV type 1 cytotoxic T lymphocyte epitopes as candidate immunogens for inclusion in Mycobacterium bovis BCG-vectored HIV vaccines.
about
Design and pre-clinical evaluation of a universal HIV-1 vaccineHeterologous Prime-Boost HIV-1 Vaccination Regimens in Pre-Clinical and Clinical TrialsRecombinant Salmonella Bacteria Vectoring HIV/AIDS Vaccines.Functional properties and epitope characteristics of T-cells recognizing natural HIV-1 variantsMulticlade human immunodeficiency virus type 1 envelope immunogens elicit broad cellular and humoral immunity in rhesus monkeys.Broad cross-clade T-cell responses to gag in individuals infected with human immunodeficiency virus type 1 non-B clades (A to G): importance of HLA anchor residue conservation.Similar T-cell immune responses induced by group M consensus env immunogens with wild-type or minimum consensus variable regions.An adjuvanted polyprotein HIV-1 vaccine induces polyfunctional cross-reactive CD4+ T cell responses in seronegative volunteers.Cross-subtype T-cell immune responses induced by a human immunodeficiency virus type 1 group m consensus env immunogenSafety and Immunogenicity of the MRKAd5 gag HIV Type 1 Vaccine in a Worldwide Phase 1 Study of Healthy AdultsSynthetic immunotherapy induces HIV virus specific Th1 cytotoxic response and death of an HIV-1 infected human cell line through classic complement activation.SHIV antigen immunization alters patterns of immune responses to SHIV/malaria coinfection and protects against life-threatening SHIV-related malaria.HLA-associated clinical progression correlates with epitope reversion rates in early human immunodeficiency virus infectionPolyvalent AIDS vaccines.STEP trial and HIV-1 vaccines inducing T-cell responses.Recombinant Salmonella enterica serovar Typhimurium as a vaccine vector for HIV-1 Gag.Human immunodeficiency virus type 1 gag-specific mucosal immunity after oral immunization with papillomavirus pseudoviruses encoding gag.CD4+ T cells from HIV-1-infected patients recognize wild-type and mutant human immunodeficiency virus-1 protease epitopes.Prediction of promiscuous peptides that bind HLA class I molecules.Analyzing the effect of peptide-HLA-binding ability on the immunogenicity of potential CD8+ and CD4+ T cell epitopes in a large dataset.Ramifications of HLA class I polymorphism and population genetics for vaccine development.
P2860
Q21092234-EF499FFF-2E17-4813-9C83-A9C664FA2EB1Q28394899-95AE0C66-E64C-4F7C-8F80-9FB6E736E670Q30358493-A731FD39-F11D-4349-AF80-A95D41DC0C2FQ33753695-05A2CB80-ADF8-4835-8DD5-723245CFEA17Q33834916-6F864980-4494-403C-A1D8-22B623FB4526Q33930297-6A8F7728-EDE4-48CC-B436-F2D8E870ED1CQ34103170-D322AAE2-643D-4D3D-872B-4680008F04CFQ34699156-F1609910-76C7-4B9F-A639-51FE5F02BC8CQ34717906-ECBF1E5C-8A1E-4105-99AE-C12755998A28Q36172965-03367CFB-355A-41CB-B53A-F182301B9D1EQ36766857-B9AFDB0E-12BB-4716-846B-8AFE9D398611Q36936342-5570E2DC-AF4F-4749-9544-FD793149CD51Q37051649-40E552A5-867E-484F-B0F4-BE7155A2FE88Q37094429-A53712F9-32DB-4845-9F7D-71CF7582DBDEQ37130450-08EE95E2-D348-496B-85DF-CF11EDBB0261Q37235277-2804EDCC-DCF5-4693-9FDC-6EA2009D16DBQ37511451-14A31A39-EDC4-482F-9EFB-DBF8A3226F22Q39280285-40E7EABB-E5F4-40B2-AFA2-A7BB72D682D3Q39605619-2836617B-9AE8-4BB9-AEEF-2D6E216173FDQ39838760-96C8FEBD-1DB6-44A6-B9C4-E23C8BDDCAB8Q52070060-7717BBC5-D45B-4CE4-9552-2784211DED17
P2860
Identification of highly conserved and broadly cross-reactive HIV type 1 cytotoxic T lymphocyte epitopes as candidate immunogens for inclusion in Mycobacterium bovis BCG-vectored HIV vaccines.
description
2000 nî lūn-bûn
@nan
2000 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Identification of highly conse ...... vis BCG-vectored HIV vaccines.
@ast
Identification of highly conse ...... vis BCG-vectored HIV vaccines.
@en
Identification of highly conse ...... vis BCG-vectored HIV vaccines.
@nl
type
label
Identification of highly conse ...... vis BCG-vectored HIV vaccines.
@ast
Identification of highly conse ...... vis BCG-vectored HIV vaccines.
@en
Identification of highly conse ...... vis BCG-vectored HIV vaccines.
@nl
prefLabel
Identification of highly conse ...... vis BCG-vectored HIV vaccines.
@ast
Identification of highly conse ...... vis BCG-vectored HIV vaccines.
@en
Identification of highly conse ...... vis BCG-vectored HIV vaccines.
@nl
P2093
P1476
Identification of highly conse ...... vis BCG-vectored HIV vaccines.
@en
P2093
Weinhold KJ
P304
P356
10.1089/08892220050140982
P577
2000-09-01T00:00:00Z